Literature DB >> 25157266

Melanoma: A new strategy to reduce morbidity and mortality.

Cameron Williams1, Christopher Quirk1, Anna Quirk1.   

Abstract

BACKGROUND: Public awareness campaigns could address risk factors for melanoma to reinforce their sun protection message. The objective of this study is to prioritise risk factors associated with malignant melanoma (MM) to improve public awareness.
DESIGN: A cross-sectional study with retrospective data analysis from 2004 to 2010.
SETTING: Western Australian Melanoma Advisory Service (WAMAS), a tertiary referral multidisciplinary organisation providing MM management advice. WAMAS data files were analysed with histologically confirmed cutaneous MM. Forty- seven patients had two or more melanomas, but the patient file was counted only once. Six MM data files with missing or incomplete information were excluded. MAIN OUTCOME MEASURES: The number of naevi, blood relatives with MM, and previous sunburns were the primary variables collected.
RESULTS: The results showed that 70.9 per cent (268/378) had previous sunburn; 40.2 per cent (152/378) had multiple naevi; and 22.5 per cent (85/378) had a positive family history. In the 110 MM data files not associated with sunburn, multiple naevi and a positive family history represented 34.5 per cent (38/110) and 20.0 per cent (22/110), respectively.
CONCLUSION: The results confirm the findings of previous studies that multiple naevi and a positive family history are important risk factors associated with MM. We suggest that MM can be detected earlier and its mortality decreased by focusing on these high-risk groups who are not targeted by current public awareness campaigns.

Entities:  

Keywords:  Risk factors; melanoma; prevention

Year:  2014        PMID: 25157266      PMCID: PMC4127957          DOI: 10.4066/AMJ.2014.1949

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  18 in total

Review 1.  Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data.

Authors:  Jürgen Bauer; Claus Garbe
Journal:  Pigment Cell Res       Date:  2003-06

2.  Who attends skin cancer screening in Western Australia? Results from the Lions Cancer Institute Skin Cancer Screening Program.

Authors:  Heather A Williams; Lin Fritschi; Alison Reid; Colin Beauchamp; Paul Katris
Journal:  Aust N Z J Public Health       Date:  2006-02       Impact factor: 2.939

3.  Moles and melanoma: a history.

Authors:  J P Bennett; P Hall
Journal:  Ann R Coll Surg Engl       Date:  1994-11       Impact factor: 1.891

Review 4.  Melanoma.

Authors:  J K Rivers
Journal:  Lancet       Date:  1996-03-23       Impact factor: 79.321

5.  Predicting melanoma risk for the Australian population.

Authors:  Victoria Mar; Rory Wolfe; John W Kelly
Journal:  Australas J Dermatol       Date:  2011-03-01       Impact factor: 2.875

6.  Risk factors in a cohort of patients with multiple primary melanoma.

Authors:  Erin McMeniman; Kathryn De'Ambrosis; Brian De'Ambrosis
Journal:  Australas J Dermatol       Date:  2010-11       Impact factor: 2.875

7.  Number of melanocytic nevi as a major risk factor for malignant melanoma.

Authors:  E A Holly; J W Kelly; S N Shpall; S H Chiu
Journal:  J Am Acad Dermatol       Date:  1987-09       Impact factor: 11.527

8.  Pigmentary traits, ethnic origin, benign nevi, and family history as risk factors for cutaneous malignant melanoma.

Authors:  C D Holman; B K Armstrong
Journal:  J Natl Cancer Inst       Date:  1984-02       Impact factor: 13.506

9.  Malignant melanoma in Italy: risks associated with common and clinically atypical melanocytic nevi.

Authors:  P Carli; A Biggeri; B Giannotti
Journal:  J Am Acad Dermatol       Date:  1995-05       Impact factor: 11.527

Review 10.  Melanoma and sunburn.

Authors:  D Whiteman; A Green
Journal:  Cancer Causes Control       Date:  1994-11       Impact factor: 2.506

View more
  1 in total

1.  Butein inhibits metastatic behavior in mouse melanoma cells through VEGF expression and translation-dependent signaling pathway regulation.

Authors:  Yu-Wei Lai; Shih-Wei Wang; Chien-Hsin Chang; Shih-Chia Liu; Yu-Jen Chen; Chih-Wen Chi; Li-Pin Chiu; Shiou-Sheng Chen; Allen W Chiu; Ching-Hu Chung
Journal:  BMC Complement Altern Med       Date:  2015-12-22       Impact factor: 3.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.